TY - JOUR AU - Jemal, A. AU - Bray, F. AU - Center, M. M. AU - Ferlay, J. AU - Ward, E. AU - Forman, D. PY - 2011 DA - 2011// TI - Global cancer statistics JO - CA Cancer J Clin VL - 61 UR - https://doi.org/10.3322/caac.20107 DO - 10.3322/caac.20107 ID - Jemal2011 ER - TY - JOUR AU - Yang, P. AU - Allen, M. S. AU - Aubry, M. C. AU - Wampfler, J. A. AU - Marks, R. S. AU - Edell, E. S. PY - 2005 DA - 2005// TI - Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 JO - Chest VL - 128 UR - https://doi.org/10.1378/chest.128.1.452 DO - 10.1378/chest.128.1.452 ID - Yang2005 ER - TY - JOUR AU - Scagliotti, G. V. AU - De, M. F. AU - Rinaldi, M. AU - Crino, L. AU - Gridelli, C. AU - Ricci, S. PY - 2002 DA - 2002// TI - Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.02.068 DO - 10.1200/JCO.2002.02.068 ID - Scagliotti2002 ER - TY - JOUR AU - Schiller, J. H. AU - Harrington, D. AU - Belani, C. P. AU - Langer, C. AU - Sandler, A. AU - Krook, J. PY - 2002 DA - 2002// TI - Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer JO - N Engl J Med VL - 346 UR - https://doi.org/10.1056/NEJMoa011954 DO - 10.1056/NEJMoa011954 ID - Schiller2002 ER - TY - JOUR AU - Fukuoka, M. AU - Wu, Y. L. AU - Thongprasert, S. AU - Sunpaweravong, P. AU - Leong, S. S. AU - Sriuranpong, V. PY - 2011 DA - 2011// TI - Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.4235 DO - 10.1200/JCO.2010.33.4235 ID - Fukuoka2011 ER - TY - JOUR AU - Hirsch, F. R. AU - Varella-Garcia, M. AU - Bunn, P. A. AU - Franklin, W. A. AU - Dziadziuszko, R. AU - Thatcher, N. PY - 2006 DA - 2006// TI - Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.3958 DO - 10.1200/JCO.2006.06.3958 ID - Hirsch2006 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. AU - Vergnenegre, A. AU - Massuti, B. AU - Felip, E. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Sequist, L. V. AU - Yang, J. C. AU - Yamamoto, N. AU - O'Byrne, K. AU - Hirsh, V. AU - Mok, T. PY - 2013 DA - 2013// TI - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.2806 DO - 10.1200/JCO.2012.44.2806 ID - Sequist2013 ER - TY - JOUR AU - Wu, Y. L. AU - Zhou, C. AU - Hu, C. P. AU - Feng, J. AU - Lu, S. AU - Huang, Y. PY - 2014 DA - 2014// TI - Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70604-1 DO - 10.1016/S1470-2045(13)70604-1 ID - Wu2014 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. L. AU - Chen, G. AU - Feng, J. AU - Liu, X. Q. AU - Wang, C. PY - 2011 DA - 2011// TI - Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70184-X DO - 10.1016/S1470-2045(11)70184-X ID - Zhou2011 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Sharma, S. V. AU - Bell, D. W. AU - Settleman, J. AU - Haber, D. A. PY - 2007 DA - 2007// TI - Epidermal growth factor receptor mutations in lung cancer JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2088 DO - 10.1038/nrc2088 ID - Sharma2007 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. AU - Yang, C. H. AU - Chu, D. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Kris, M. G. AU - Natale, R. B. AU - Herbst, R. S. AU - Lynch, T. J. AU - Prager, D. AU - Belani, C. P. PY - 2003 DA - 2003// TI - Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JO - JAMA VL - 290 UR - https://doi.org/10.1001/jama.290.16.2149 DO - 10.1001/jama.290.16.2149 ID - Kris2003 ER - TY - JOUR AU - Rosell, R. AU - Moran, T. AU - Queralt, C. AU - Porta, R. AU - Cardenal, F. AU - Camps, C. PY - 2009 DA - 2009// TI - Screening for epidermal growth factor receptor mutations in lung cancer JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0904554 DO - 10.1056/NEJMoa0904554 ID - Rosell2009 ER - TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Kobayashi, K. AU - Sugawara, S. AU - Oizumi, S. AU - Isobe, H. PY - 2010 DA - 2010// TI - Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909530 DO - 10.1056/NEJMoa0909530 ID - Maemondo2010 ER - TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. AU - Negoro, S. AU - Okamoto, I. AU - Tsurutani, J. PY - 2010 DA - 2010// TI - Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Douillard, J. Y. AU - Ostoros, G. AU - Cobo, M. AU - Ciuleanu, T. AU - McCormack, R. AU - Webster, A. PY - 2014 DA - 2014// TI - First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study JO - Br J Cancer VL - 110 UR - https://doi.org/10.1038/bjc.2013.721 DO - 10.1038/bjc.2013.721 ID - Douillard2014 ER - TY - JOUR AU - Febbo, P. G. AU - Ladanyi, M. AU - Aldape, K. D. AU - De Marzo, A. M. AU - Hammond, M. E. AU - Hayes, D. F. PY - 2011 DA - 2011// TI - NCCN task force report: evaluating the clinical utility of tumor markers in oncology JO - J Natl Compr Cancer Netw VL - 9 UR - https://doi.org/10.6004/jnccn.2011.0137 DO - 10.6004/jnccn.2011.0137 ID - Febbo2011 ER - TY - JOUR AU - Keedy, V. L. AU - Temin, S. AU - Somerfield, M. R. AU - Beasley, M. B. AU - Johnson, D. H. AU - McShane, L. M. PY - 2011 DA - 2011// TI - American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.31.8923 DO - 10.1200/JCO.2010.31.8923 ID - Keedy2011 ER - TY - JOUR AU - Pirker, R. AU - Herth, F. J. AU - Kerr, K. M. AU - Filipits, M. AU - Taron, M. AU - Gandara, D. PY - 2010 DA - 2010// TI - Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop JO - J Thorac Oncol VL - 5 UR - https://doi.org/10.1097/JTO.0b013e3181f1c8de DO - 10.1097/JTO.0b013e3181f1c8de ID - Pirker2010 ER - TY - JOUR AU - Reck, M. AU - Popat, S. AU - Reinmuth, N. AU - De, R. D. AU - Kerr, K. M. AU - Peters, S. PY - 2014 DA - 2014// TI - Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu199 DO - 10.1093/annonc/mdu199 ID - Reck2014 ER - TY - JOUR AU - Angulo, B. AU - Conde, E. AU - Suarez-Gauthier, A. AU - Plaza, C. AU - Martinez, R. AU - Redondo, P. PY - 2012 DA - 2012// TI - A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0043842 DO - 10.1371/journal.pone.0043842 ID - Angulo2012 ER - TY - JOUR AU - Goto, K. AU - Satouchi, M. AU - Ishii, G. AU - Nishio, K. AU - Hagiwara, K. AU - Mitsudomi, T. PY - 2012 DA - 2012// TI - An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds121 DO - 10.1093/annonc/mds121 ID - Goto2012 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Marchetti, A. AU - Felicioni, L. AU - Buttitta, F. PY - 2006 DA - 2006// TI - Assessing EGFR mutations JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMc052564 DO - 10.1056/NEJMc052564 ID - Marchetti2006 ER - TY - JOUR AU - Querings, S. AU - Altmuller, J. AU - Ansen, S. AU - Zander, T. AU - Seidel, D. AU - Gabler, F. PY - 2011 DA - 2011// TI - Benchmarking of mutation diagnostics in clinical lung cancer specimens JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0019601 DO - 10.1371/journal.pone.0019601 ID - Querings2011 ER - TY - JOUR AU - Vallee, A. AU - Le Loupp, A. G. AU - Denis, M. G. PY - 2013 DA - 2013// TI - Efficiency of the Therascreen(R) RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas JO - Clin Chim Acta VL - 429C ID - Vallee2013 ER - TY - JOUR AU - Ellison, G. AU - Zhu, G. AU - Moulis, A. AU - Dearden, S. AU - Speake, G. AU - McCormack, R. PY - 2013 DA - 2013// TI - EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples JO - J Clin Pathol VL - 66 UR - https://doi.org/10.1136/jclinpath-2012-201194 DO - 10.1136/jclinpath-2012-201194 ID - Ellison2013 ER - TY - JOUR AU - Hagiwara, K. AU - Kobayashi, K. PY - 2013 DA - 2013// TI - Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer JO - Cancer Sci VL - 104 UR - https://doi.org/10.1111/cas.12081 DO - 10.1111/cas.12081 ID - Hagiwara2013 ER - TY - JOUR AU - Garrido, P. AU - de, C. J. AU - Concha, A. AU - Felip, E. AU - Isla, D. AU - Lopez-Rios, F. PY - 2012 DA - 2012// TI - Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) JO - Clin Transl Oncol VL - 14 UR - https://doi.org/10.1007/s12094-012-0806-2 DO - 10.1007/s12094-012-0806-2 ID - Garrido2012 ER - TY - JOUR AU - Oxnard, G. R. AU - Arcila, M. E. AU - Sima, C. S. AU - Riely, G. J. AU - Chmielecki, J. AU - Kris, M. G. PY - 2011 DA - 2011// TI - Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2692 DO - 10.1158/1078-0432.CCR-10-2692 ID - Oxnard2011 ER - TY - JOUR AU - Yu, H. A. AU - Arcila, M. E. AU - Rekhtman, N. AU - Sima, C. S. AU - Zakowski, M. F. AU - Pao, W. PY - 2013 DA - 2013// TI - Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2246 DO - 10.1158/1078-0432.CCR-12-2246 ID - Yu2013 ER - TY - JOUR AU - Chaft, J. E. AU - Oxnard, G. R. AU - Sima, C. S. AU - Kris, M. G. AU - Miller, V. A. AU - Riely, G. J. PY - 2011 DA - 2011// TI - Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-1468 DO - 10.1158/1078-0432.CCR-11-1468 ID - Chaft2011 ER - TY - JOUR AU - Riely, G. J. AU - Kris, M. G. AU - Zhao, B. AU - Akhurst, T. AU - Milton, D. T. AU - Moore, E. PY - 2007 DA - 2007// TI - Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0560 DO - 10.1158/1078-0432.CCR-07-0560 ID - Riely2007 ER - TY - JOUR AU - Lo, P. C. AU - Dahlberg, S. E. AU - Nishino, M. AU - Johnson, B. E. AU - Sequist, L. V. AU - Jackman, D. M. PY - 2015 DA - 2015// TI - Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29397 DO - 10.1002/cncr.29397 ID - Lo2015 ER - TY - JOUR AU - Park, K. AU - Yu, C. J. AU - Kim, S. W. AU - Lin, M. C. AU - Sriuranpong, V. AU - Tsai, C. M. PY - 2016 DA - 2016// TI - First-line Erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2015.4921 DO - 10.1001/jamaoncol.2015.4921 ID - Park2016 ER - TY - JOUR AU - Soria, J. C. AU - Wu, Y. L. AU - Nakagawa, K. AU - Kim, S. W. AU - Yang, J. J. AU - Ahn, M. J. PY - 2015 DA - 2015// TI - Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00121-7 DO - 10.1016/S1470-2045(15)00121-7 ID - Soria2015 ER - TY - JOUR AU - Janne, P. A. AU - Yang, J. C. AU - Kim, D. W. AU - Planchard, D. AU - Ohe, Y. AU - Ramalingam, S. S. PY - 2015 DA - 2015// TI - AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411817 DO - 10.1056/NEJMoa1411817 ID - Janne2015 ER - TY - JOUR AU - Inoue, A. AU - Kobayashi, K. AU - Maemondo, M. AU - Sugawara, S. AU - Oizumi, S. AU - Isobe, H. PY - 2013 DA - 2013// TI - Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mds214 DO - 10.1093/annonc/mds214 ID - Inoue2013 ER - TY - JOUR AU - Paz-Ares, L. AU - Soulieres, D. AU - Moecks, J. AU - Bara, I. AU - Mok, T. AU - Klughammer, B. PY - 2014 DA - 2014// TI - Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC JO - J Cell Mol Med VL - 18 UR - https://doi.org/10.1111/jcmm.12278 DO - 10.1111/jcmm.12278 ID - Paz-Ares2014 ER -